Revenues Not Telling The Story For Bristol-Myers Squibb Company (NYSE:BMY)

There wouldn't be many who think Bristol-Myers Squibb Company's (NYSE:BMY) price-to-sales (or "P/S") ratio of 2.5x is worth a mention when the median P/S for the Pharmaceuticals industry in the United States is similar at about 2.9x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.

See our latest analysis for Bristol-Myers Squibb

How Has Bristol-Myers Squibb Performed Recently?

With revenue growth that's inferior to most other companies of late, Bristol-Myers Squibb has been relatively sluggish. Perhaps the market is expecting future revenue performance to lift, which has kept the P/S from declining. If not, then existing shareholders may be a little nervous about the viability of the share price.

If you'd like to see what analysts are forecasting going forward, you should check out our free report on Bristol-Myers Squibb.

Is There Some Revenue Growth Forecasted For Bristol-Myers Squibb?

In order to justify its P/S ratio, Bristol-Myers Squibb would need to produce growth that's similar to the industry.

Taking a look back first, we see that the company managed to grow revenues by a handy 5.6% last year. Although, the latest three year period in total hasn't been as good as it didn't manage to provide any growth at all. Accordingly, shareholders probably wouldn't have been overly satisfied with the unstable medium-term growth rates.

Shifting to the future, estimates from the analysts covering the company suggest revenue growth is heading into negative territory, declining 2.1% per annum over the next three years. That's not great when the rest of the industry is expected to grow by 19% per annum.

In light of this, it's somewhat alarming that Bristol-Myers Squibb's P/S sits in line with the majority of other companies. Apparently many investors in the company reject the analyst cohort's pessimism and aren't willing to let go of their stock right now. There's a good chance these shareholders are setting themselves up for future disappointment if the P/S falls to levels more in line with the negative growth outlook.

The Bottom Line On Bristol-Myers Squibb's P/S

Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.

It appears that Bristol-Myers Squibb currently trades on a higher than expected P/S for a company whose revenues are forecast to decline. With this in mind, we don't feel the current P/S is justified as declining revenues are unlikely to support a more positive sentiment for long. If the poor revenue outlook tells us one thing, it's that these current price levels could be unsustainable.

Before you take the next step, you should know about the 2 warning signs for Bristol-Myers Squibb that we have uncovered.

If you're unsure about the strength of Bristol-Myers Squibb's business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.